TEK
ENSG00000120156
Target class
Kinase
Chromosome
9
Approved drugs
2
Clinical candidates (approved and in development)
8
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- Yes
- Target name
- TEK
- Gene name
- TEK receptor tyrosine kinase
- Gene symbol
- TEK
- Previous gene symbols
- VMCM
- Protein name
- Angiopoietin-1 receptor (EC 2.7.10.1) (Endothelial tyrosine kinase) (Tunica interna endothelial cell kinase) (Tyrosine kinase with Ig and EGF homology domains-2) (Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2) (p140 TEK) (CD antigen CD202b)
- TIE2
- TIE-2
- VMCM1
- CD202b
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|Fibronectin type III domain containing|Immunoglobulin like domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 50.74
- Tissue specificity (Gini)
- 0.426
- Tissue specificity (tau)
- 0.828
- KEGG gene identifiers
- hsa:7010
- Protein interaction confidence
- 0.815547
- Protein interaction partners
- 75
- R-HSA-210993
- R-HSA-5673001
- End position
- 27232092
- Start position
- 27109030
- Chromosome
- 9
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein. Cell junction . Cell junction, focal adhesion . Cytoplasm, cytoskeleton. Secreted . Note=Recruited to cell-cell contacts in quiescent endothelial cells (PubMed:18425119, PubMed:18425120). Colocalizes with the actin cytoskeleton and at actin stress fibers during cell spreading. Recruited to the lower surface of migrating cells, especially the rear end of the cell. Proteolytic processing gives rise to a soluble extracellular domain that is secreted (PubMed:11806244). .
- Plasma membrane
- PubMed 18425119
- PubMed 18425120
- PubMed 19079259
- PubMed 27270174
- PubMed 19293632
- PubMed 11806244
- Tissue specificity (tau)
- 0.827798
- Expression inequality (Gini)
- 0.425689
Expression in transcripts per million
- Lung
- 50.74
- Adipose - Subcutaneous
- 32.65
- Adipose - Visceral (Omentum)
- 26.35
- Breast - Mammary Tissue
- 23.38
- Thyroid
- 21.75
Expression in transcripts per million
- Lung50.74
- Adipose - Subcutaneous32.65
- Adipose - Visceral (Omentum)26.35
- Breast - Mammary Tissue23.38
- Thyroid21.75
- Spleen19.54
- Kidney - Medulla17.8
- Uterus17.65
- Artery - Coronary15.96
- Nerve - Tibial14.25
- Fallopian Tube12.81
- Cervix - Endocervix12.69
- Kidney - Cortex11.36
- Artery - Tibial10.62
- Cervix - Ectocervix10.55
- Esophagus - Gastroesophageal Junction10.3
- Esophagus - Muscularis10.09
- Adrenal Gland9.95
- Heart - Atrial Appendage9.63
- Artery - Aorta9.56
- Heart - Left Ventricle9.36
- Small Intestine - Terminal Ileum8.49
- Colon - Sigmoid8.48
- Bladder8.17
- Vagina7.16
And 29 more, listed on the interactive page.
- GO:0001525
- GO:0001938
- GO:0002040
- GO:0007166
- GO:0007169
- GO:0007267
- GO:0010595
- GO:0016525
- GO:0032878
- GO:0034446
- GO:0035022
- GO:0035025
- GO:0043066
- GO:0043114
- GO:0043410
- GO:0045766
- GO:0048014
- GO:0050728
- GO:0051894
- GO:0051897
- GO:0060216
- GO:0070374
- GO:0071260
- GO:1902533
- GO:2000351
- GO:0001725
- GO:0005576
- GO:0005884
- GO:0005886
- GO:0005902
- GO:0005911
- GO:0009925
- GO:0009986
- GO:0016323
- GO:0016324
- GO:0045121
- GO:0070161
- GO:0004672
- GO:0004713
- GO:0004714
- GO:0005515
- GO:0019199
- GO:0038023
- GO:0042802
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hTie2, is one of one assay component(s) measured or calculated from the NVS_ENZ_hTie2 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (555)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- 68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis
- 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
- 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
- 68Ga-PSMA PET/CT in Prostate Cancer
- 68Ga-PSMA PET/CT in Prostate Cancer
- 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
- 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Drugs (8)
- Altiratinib Tyrosine-protein kinase TIE-2 inhibitor
- CE-245677 Tyrosine-protein kinase TIE-2 inhibitor
- CEP-11981 Tyrosine-protein kinase TIE-2 inhibitor
- Foretinib Tyrosine-protein kinase TIE-2 inhibitor
- Glesatinib Tyrosine-protein kinase TIE-2 inhibitor
- Pexmetinib Tyrosine-protein kinase TIE-2 inhibitor
- Regorafenib Tyrosine-protein kinase TIE-2 inhibitor
- Vandetanib Tyrosine-protein kinase TIE-2 inhibitor